Research Topics
Species | R B WalterSummaryAffiliation: Fred Hutchinson Cancer Research Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Gemcitabine-associated hemolytic-uremic syndromeRoland B Walter
Medical Clinic B and Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
Am J Kidney Dis 40:E16. 2002..Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported...- Life-threatening thrombocytopenia associated with acute Epstein-Barr virus infection in an older adultR B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
Ann Hematol 81:672-5. 2002..In this report we also briefly summarize the literature on EBV-associated severe thrombocytopenia... 
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patientsRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 121:2424-31. 2013..In conclusion, in the 2008 WHO classification scheme, FAB subclassification does not provide prognostic information for "AML, NOS" cases if data on NPM1 and CEBPA mutations are available...
Acute myeloid leukemia stem cells and CD33-targeted immunotherapyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Blood 119:6198-208. 2012..Herein, we review studies on the nature of stem cells in AML, discuss clinical data on the effectiveness of CD33-directed therapy, and consider the mechanistic basis for success and failure in various AML subsets...- Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemiaRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Haematologica 97:739-42. 2012..0%); group 2A, 6 of 13 (46.2%); and group 2B, none of 8 (0%). These data indicate that vorinostat+gemtuzumab ozogamicin has activity that is mostly confined to patients with normal karyotype disease. ClinicalTrial.gov: NCT00673153... - High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology groupRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA
J Clin Oncol 28:2831-8. 2010..To evaluate the prognostic significance of the integrin cell adhesion molecule very late antigen-4 (VLA-4) in acute myeloid leukemia (AML)... - Pretargeted radioimmunotherapy for hematologic and other malignanciesRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Cancer Biother Radiopharm 25:125-42. 2010..With continued research, PRIT-based treatment strategies promise to become cornerstones to improved outcomes for cancer patients despite their complexities... - Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remissionR B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Leukemia 24:1276-82. 2010..16 (0.52-2.61), P=0.71). These data indicate that URD HCT can provide long-term survival for CR1 AML; outcomes for 10/10 URD HCT, and possibly 9/10 URD HCT, suggest that this modality should be considered in the absence of a suitable MRD... - Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 116:2420-8. 2010..We also suggest strategies for trial design improvement. Although our focus is on the treatment of AML, the principles that we highlight should be broadly applicable to the evaluation of new treatments for a variety of diseases... - Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemiaRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 29:1190-7. 2011..Hitherto, little attention has been given to the prognostic impact of pretransplantation minimal residual disease (MRD)... - Outpatient management following intensive induction chemotherapy for myelodysplastic syndromes and acute myeloid leukemia: a pilot studyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190 Seattle, WA 98109 1024, USA
Haematologica 96:914-7. 2011..08), and incurred lower median daily charges ($3,270 vs. $5,467; P=0.01) than controls. Thus, early discharge of selected patients appears, safe and may reduce cost and resource utilization. (ClinicalTrials.gov Identifier: NCT00844441)... - Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) studyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
J Clin Oncol 29:2424-31. 2011..Herein, we used a large prospective cohort study to examine these associations... - Vitamin, mineral, and specialty supplements and risk of hematologic malignancies in the prospective VITamins And Lifestyle (VITAL) studyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Cancer Epidemiol Biomarkers Prev 20:2298-308. 2011..Increasing evidence suggests that nutrients from fruits and vegetables have chemoprotective effects on various cancers including hematologic malignancies, but the effects of nutritional supplements are poorly examined... - Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignmentRoland B Walter
Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 190, Seattle, WA 98109 1024, USA
J Clin Oncol 29:4417-23. 2011..Eligibility for intensive AML treatment protocols is therefore typically based on age as the implied principal predictor of TRM, although other health- and disease-related factors modulate this age effect... - Cancer risk associated with long-term use of acetaminophen in the prospective VITamins and lifestyle (VITAL) studyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Cancer Epidemiol Biomarkers Prev 20:2637-41. 2011.... - Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center StudyRoland B Walter
Clinical Research Division and Southwest Oncology Group Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
J Clin Oncol 28:1766-71. 2010..Although the significance of CRp for survival remains unclear, reports of AML trials frequently combine CR with CRp rather than considering CR as a separate entity... - Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenograftsRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 111:4813-6. 2008..These data suggest that further study of this antibody combination for clinical use in AML is warranted... - Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptorRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109 1024, USA
Traffic 9:267-79. 2008.... - Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cellsRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 102:1466-73. 2003..Because MK-571 and CSA failed to affect cytotoxicity in a portion of Pgp-positive/MRP-positive AML samples, additional resistance mechanisms are likely important... - Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicityRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
Blood 105:1295-302. 2005.... - PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanismRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 106:3584-93. 2005.... - CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
Blood 109:4168-70. 2007..The inverse relationship between CD33 and Pgp suggests a maturation-stage-dependent expression of both proteins, and offers the rationale for using cell differentiation-promoting agents to enhance GO-induced cytotoxicity... - ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2Roland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 373, Seattle, WA 98109 1024, USA
J Leukoc Biol 83:200-11. 2008..Our studies show that restraint of CD33 internalization through the intracellular domain is relieved partly when the ITIMs are phosphorylated and show that Shp1 and Shp2 can modulate this process... - The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicinRoland B Walter
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1-100, PO Box 19024, Seattle, WA 98109-1024, USA
Blood 103:4276-84. 2004..Since PK11195 is well tolerated in humans as a single agent, its further study as a multifunctional chemosensitizer for anti-AML therapies, including GO-based therapies, is warranted... - Acute severe anaemia in an elderly patient with hereditary sphaerocytosisA Imhof
Department of Medicine, Regionalspital, Langenthal, Switzerland
Postgrad Med J 79:244, 246. 2003 - Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational studyAlexander Imhof
Department of Internal Medicine, Medical Clinic B, University Hospital, Zurich, Switzerland
Clin Infect Dis 36:943-51. 2003..In conclusion, continuous infusion of AmB-d escalated to 2.0 mg/kg/day seems not to cause additional impairment of vital organ functions and to be well tolerated by most patients... - Safety of lumbar puncture for adults with acute leukemia and restrictive prophylactic platelet transfusionStephan R Vavricka
Department of Internal Medicine, University Hospital of Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
Ann Hematol 82:570-3. 2003.... - Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineageEsther B Bachli
Department of Medicine, University Hospital of Zurich, CH 8091 Zurich, Switzerland
J Leukoc Biol 79:312-8. 2006.... - Expression of the hemoglobin scavenger receptor (CD163/HbSR) as immunophenotypic marker of monocytic lineage in acute myeloid leukemiaRoland B Walter
Blood 101:3755-6. 2003